Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 121, Issue 3, pp 291–293 | Cite as

Effect of nimodipine on cell calcium concentration and platelet aggregation in patients with ischemic stroke

  • N. A. Pryanikova
  • A. S. Dukhanin
  • L. V. Stakhovskaya
  • N. S. Chekneva
Experimental Methods for Clinical Practice
  • 32 Downloads

Abstract

The rate of spontaneous platelet aggregation is 1.5-2-fold increased in patients with ischemic stroke in comparison with control values. Monotherapy with nimodipine lowers parameters of spontaneous platelet aggregation virtually to normal values. Nimodipine inhibits ADP-induced aggregation but does not affect the ADP affinity of platelet receptors. Experiments with a Fura 2-AM fluorescent probe show that the basal calcium level in platelets from patients with ischemic stroke reliably surpassed that in healthy donors. Nimodipine inhibits the ADP-induced rise of the cell calcium level.

Key Words

calcium channel blockers ischemic stroke platelets 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. V. Avdonin and V. A. Tkachuk,Receptors and Intracellular Calcium [in Russian], Moscow (1994).Google Scholar
  2. 2.
    S. E. Akopov, G. S. Grigoryan, A. V. Kazaryan,et al., Zh. Nevropatol. Psikhiatr., No 7, 63–66 (1991).Google Scholar
  3. 3.
    Sh. E. Atakhanov, L. M. Resvich, R. B. Devero,et al., Kardiologiya,32, No 1, 66–67 (1992).PubMedGoogle Scholar
  4. 4.
    A. I. Beketov and T. M. Gromova,Farmakol. Toksikol.,51, No 2, 103–107 (1988).PubMedGoogle Scholar
  5. 5.
    A. Yu. Verkhovskii, N. P. Poviraev, and M. A. Medvedev,Zh. Nevropatol. Psikhiatr., No 9, 54–58 (1988).Google Scholar
  6. 6.
    E. S. Gabrielyan and S. E. Akopov,Zh. Eksp. Klin. Med.,22, No 4, 269–273 (1982).Google Scholar
  7. 7.
    V. V. Kolomiets,Kardiologiya,30, No 7, 26–28 (1990).PubMedGoogle Scholar
  8. 8.
    P. G. Kostyuk,Calcium and Cell Excitability [in Russian], Moscow (1986).Google Scholar
  9. 9.
    K. M. Lakin, E. M. Manevich, and A. G. Mulyar,Farmakol. Toksikol.,50, No 5, 78–88 (1987).PubMedGoogle Scholar
  10. 10.
    V. B. Razumov, A. B. Gutkin, and V. V. Omel'yanovskii,Kardiologiya,28, No 5, 118–122 (1988).PubMedGoogle Scholar
  11. 11.
    I. K. Shkhvatsabaya, A. N. Kravchenko, P. V. Avdonin,et al., —Ibid.,28, No 5, pp. 72–77.Google Scholar
  12. 12.
    Z. A. Gabbasov, E. G. Popov, I. Yu. Gavrilov, and E. Ya. Pozin,Thromb. Res.,54, 215–223 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Malgaroli, D. Milani, J. Meidolesi, and T. Pozzan,J. Cell Biol.,105, 2145–2155 (1987).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • N. A. Pryanikova
    • 1
  • A. S. Dukhanin
    • 1
  • L. V. Stakhovskaya
    • 1
  • N. S. Chekneva
    • 1
  1. 1.Department of Molecular Pharmacology and Department of Neurology and Neurosurgery No. 2Russian State Medical UniversityMoscow

Personalised recommendations